Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia

Links shared publicly online about this topic.

994
total visits

Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States. Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy.

View full resource at news-medical.net

Tags: Anemia, Anemia Medication, Kidney Health, Urinary System, Pharma, Clinical Trial, Procrit, Eprex